Abstract
The management of haemorrhage or risk of haemorrhage in anticoagulated patients increasingly involves those providing services for haemophilia. This is particularly so in the use of prothrombin complex concentrates where experience of the use of these products exists almost entirely within haemophilia centres. As the majority of bleeding anticoagulated patients present to hospitals that do not have haemophila centres, and where there is little experience in the use of PCCs, there is clearly a need for practical guidelines to guide use of these products. Clinicians must be made aware of the potential benefits and risks of using concentrated coagulation factors prepared from large plasma pools. A key aspects of the safe use of PCCs is the careful selection of the clinical indications for their use. Only those patients with or at risk from life-threatening haemorrhage should be treated. And where a licensed product is available, this should be used in preference to those that are not. Data are lacking on the comparative efficacy of products containing factors II, VII, IX (FIX) and X against those lacking factor VII. There is evidence to show that factor VII levels may be extremely low in patients with high INRs, suggesting that overanticoagulated patients may benefit more from PCCs containing all four vitamin K-dependent factors. The optimal dose of PCC required to reverse anticoagulation is not fully established but does depend on the degree of the coagulation defect. The experience of this group suggests that doses between 25 IU FIX/kg and 50 IU FIX/kg are effective. We present a practical protocol for the use of PCC in reversal of coumarin-induced anticoagulation.
Highlights
Community-acquired pneumonia remains a common ventilation (MV) were randomized into two groups: one group was condition worldwide
This study shows that the inhibition of the intramyocardial expression of tumour necrosis factor (TNF)-α and of its secondary mediator COX-2 related to moderate hypothermia during cardiopulmonary bypass (CPB) is associated with the inhibition of p38 mitogen-activated protein kinase (MAPK)–acute pancreatitis (AP)-1, but not of the NF-κB pathway
Purification, characterization, and analytical mass assignment of inducible nitric oxide synthase (iNOS) from DLD-1-5B2 cells are in progress to provide mass standardization for the iNOS immunoassay
Summary
Community-acquired pneumonia remains a common ventilation (MV) were randomized into two groups: one group was condition worldwide. Methods Eighty-one consecutive patients (age 63 ± 16 years, male n = 51, SAPS 2 score 49 ± 11, mechanical ventilation n = 50, vasopressors n = 56, renal failure n = 19, postoperative n = 23) admitted to the ICU during a 3-month period were evaluated. Probiotics administration was suggested to reduce the incidence of infections and the overall morbidity and mortality in surgical patients The aim of this prospective randomized clinical trial was to assess the effects of a combination formula of probiotics and prebiotics (Synbiotic 2000Forte; Medifarm, Sweden) versus prebiotics only (fiber) in critically ill, long-term mechanically ventilated trauma patients. This study examines the acute patient outcomes associated with the evolution of early total care to damage control orthopaedics for multiply injured patients with femoral shaft fractures
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
